# Evaluation of ICP-B794 in Patients With Advanced Solid Tumors

> **NCT07136558** · PHASE1 · NOT_YET_RECRUITING · sponsor: **Beijing InnoCare Pharma Tech Co., Ltd.** · enrollment: 410 (estimated)

## Conditions studied

- Advanced Solid Tumors

## Interventions

- **DRUG:** ICP-B794

## Key facts

- **NCT ID:** NCT07136558
- **Lead sponsor:** Beijing InnoCare Pharma Tech Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-08
- **Primary completion:** 2029-06
- **Final completion:** 2030-12
- **Target enrollment:** 410 (ESTIMATED)
- **Last updated:** 2025-08-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07136558

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07136558, "Evaluation of ICP-B794 in Patients With Advanced Solid Tumors". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT07136558. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*